AIM: To assess the progression of bronchial reactivity (BR) and incidence of bronchial hyperreactivity (BH), exercise-induced bronchoconstriction (EIB) and asthma in triathletes over 2 years. METHODS: Subjects were seven athletes from the Swiss national triathlon team (mean (SD) age 24.3 (4.8) years), who initially were not asthmatic, not treated with antiasthmatic medication, and who had performed at international level for more than 3 consecutive years (2001-2003). To assess BR, BH and EIB, subjects ran on a 400 m track for 8 min at intensities equal to the anaerobic threshold. Tests were conducted in ambient temperatures of 4.4 (2.8) degrees C, -8.8 (2.4) degrees C and 3.6 (1.5) degrees C, and humidity of 52 (16)%, 83 (13)% and 93 (2)%. Forced expiratory volume in 1 s (FEV(1)) was measured before and at 2, 5, 10 and 15 min after EIB, and 5 min after inhalation of a beta2 agonist. Two methods were used to calculate the incidence: (1) the standard assessment; (2) extrapolation of the decrease in FEV(1) to the BH limit. RESULTS: BR increased significantly in the seven athletes (FEV(1): year, p = 0.04; year x EIB, p = 0.002; EIB p<0.001). Within 2 years, BR had increased significantly and even reached BH in some athletes. Three athletes exhibited BH. After extrapolation of the decrease in FEV(1) in all seven athletes, the limit of 10% by definition for BH was determined to occur within 1.77-4.81 years, resulting in 21-57% of athletes with newly developed BH per year. CONCLUSION: Athletes develop EIB quickly, a rate of increase 195-286 times that of the normal rate for development of asthma.
AIM: To assess the progression of bronchial reactivity (BR) and incidence of bronchial hyperreactivity (BH), exercise-induced bronchoconstriction (EIB) and asthma in triathletes over 2 years. METHODS: Subjects were seven athletes from the Swiss national triathlon team (mean (SD) age 24.3 (4.8) years), who initially were not asthmatic, not treated with antiasthmatic medication, and who had performed at international level for more than 3 consecutive years (2001-2003). To assess BR, BH and EIB, subjects ran on a 400 m track for 8 min at intensities equal to the anaerobic threshold. Tests were conducted in ambient temperatures of 4.4 (2.8) degrees C, -8.8 (2.4) degrees C and 3.6 (1.5) degrees C, and humidity of 52 (16)%, 83 (13)% and 93 (2)%. Forced expiratory volume in 1 s (FEV(1)) was measured before and at 2, 5, 10 and 15 min after EIB, and 5 min after inhalation of a beta2 agonist. Two methods were used to calculate the incidence: (1) the standard assessment; (2) extrapolation of the decrease in FEV(1) to the BH limit. RESULTS: BR increased significantly in the seven athletes (FEV(1): year, p = 0.04; year x EIB, p = 0.002; EIB p<0.001). Within 2 years, BR had increased significantly and even reached BH in some athletes. Three athletes exhibited BH. After extrapolation of the decrease in FEV(1) in all seven athletes, the limit of 10% by definition for BH was determined to occur within 1.77-4.81 years, resulting in 21-57% of athletes with newly developed BH per year. CONCLUSION: Athletes develop EIB quickly, a rate of increase 195-286 times that of the normal rate for development of asthma.
Authors: Ilkka Helenius; Paula Rytilä; Seppo Sarna; Aki Lumme; Miia Helenius; Ville Remes; Tari Haahtela Journal: J Allergy Clin Immunol Date: 2002-06 Impact factor: 10.793
Authors: Babette M Pluim; Olivier de Hon; J Bart Staal; Jacqueline Limpens; Harm Kuipers; Shelley E Overbeek; Aeilko H Zwinderman; Rob J P M Scholten Journal: Sports Med Date: 2011-01-01 Impact factor: 11.136
Authors: Konstantinos M Pigakis; Vasileios T Stavrou; Ioannis Pantazopoulos; Zoe Daniil; Aggeliki K Kontopodi; Konstantinos Gourgoulianis Journal: Cureus Date: 2022-01-03